Objectives: To characterize different stages of Parkinson disease (PD)-related cognitive decline using diffusion tensor imaging (DTI) and investigate potential relationships between cognition and microstructural integrity of primary white matter tracts.
Conventional structural MRI has generated mixed evidence as to whether gray matter atrophy suitably distinguishes PD-MCI from either PD with normal cognition (PD-N) or PD-D. 7, 8 Diffusion tensor imaging (DTI) provides a quantitative measure of microstructural integrity and organization, and is thus more suited to subtle damage not evident with conventional MRI. [9] [10] [11] DTI has identified abnormalities in PD-D, 12, 13 and some evidence suggests that it may also reveal degeneration in patients without dementia who have lesser cognitive impairment. 10, 12 We therefore used DTI to investigate 1) whether the imaging profile of formally diagnosed PD-MCI 4 is more similar to the "malignancy" evident in patients with PD-D and can be distinguished from those with PD-N and controls, and 2) whether impairments in specific cognitive domains produce unique patterns of microstructural damage.
METHODS Subjects. A convenience sample of 118 participants meeting the United Kingdom Parkinson's Disease Society's criteria for idiopathic PD 14 was recruited from the Movement Disorders Clinic at the New Zealand Brain Research Institute (Christchurch, New Zealand) from May 2007 to September 2010. Individuals representative of the full spectrum of cognitive status in PD were invited to participate. Exclusion criteria included atypical parkinsonian disorder; prior learning disability; history of other neurologic conditions including moderate-severe head injury, stroke, vascular dementia; and major psychiatric or medical illness in the previous 6 months. The control group comprised 38 healthy volunteers matched to the mean characteristics of the PD sample (age, sex, and years of education). Neuroradiologic screening (R.J.K.) excluded participants showing moderate-severe white matter disease (1 control, 4 PD), marked cerebral atrophy (1 PD), or cerebellar infarcts (1 control). A further 4 PD subjects and 1 control were excluded because of excessive motion or extreme susceptibility artifacts. Three controls met our criteria for MCI and were excluded. Analyses were conducted on the remaining 109 PD and 32 control subjects.
Standard protocol approvals, registrations, and patient consents. All subjects gave written consent, with additional consent from a significant other when appropriate. The study was approved by the Regional Ethics Committee of the New Zealand Ministry of Health.
Diagnostic criteria and assessment. The Unified Parkinson's Disease Rating Scale (UPDRS; part III) 15 was used to assess motor impairment. Comprehensive neuropsychological testing (detailed previously 3, 7, 16 ) classified the patients with PD as cognitively normal (PD-N; n 5 63), with mild cognitive impairment (PD-MCI; n 5 28), or with dementia (PD-D; n 5 18). Dementia diagnosis was based on Movement Disorder Society (MDS) Task Force criteria. 17 MCI cases had unimpaired functional activities of daily living, as verified by interview with a significant other, but scored $1.5 SDs below normative data on at least 2 measures within at least 1 of 4 MDS cognitive domains (executive function; attention, working memory, and processing speed; learning and memory; and visuospatial/visuoperceptual function). These criteria are consistent with MDS diagnostic criteria for PD-MCI 4 and provide clear group separation. 3 Within each cognitive domain, standardized scores from the constituent neuropsychological tests were averaged to provide individual cognitive domain scores; global cognition for each participant was expressed as an aggregate z score obtained by averaging these 4 domain scores. At the time of assessment, 50 subjects with PD were drug naive for antiparkinsonian medication. Motor, cognitive, and MRI assessments in the remaining 59 PD participants were performed on medication, with no change to their usual drug regimen. Daily dopaminergic medications were standardized into a levodopa equivalent dose (LED). 18 MRI acquisition. Imaging was conducted on a 3-tesla General Electric HDxt scanner (GE Healthcare, Waukesha, WI) with an 8-channel head coil. A 2-dimensional diffusion-weighted, spin-echo, echo planar imaging sequence was used to measure microstructural integrity, with diffusion weighting in 28 uniformly distributed directions (b 5 1,000 s/mm MRI preprocessing. Image preprocessing and statistical analyses were performed using tract-based spatial statistics (TBSS) 19 in FSL 4.1.6 (www.fmrib.ox.ac.uk/fsl). Diffusion-weighted images were motion-and eddy current distortion-corrected. The diffusion tensor was then calculated at each voxel using DTIFIT, producing fractional anisotropy (FA) and mean diffusivity (MD) images, and then brain-extracted using BET. All FA images were aligned to a common space (FMRIB58 FA template) using the nonlinear registration tool FNIRT. The mean FA image was thinned (FA .0.25) to create a mean FA skeleton that represented the centers of all tracts common to the group. Each subject's aligned FA image was then projected onto this common skeleton, a procedure that minimizes misalignment more prevalent in standard registration procedures. 19 The nonlinear warps and skeleton projection were then applied to MD images to create a separate skeleton representing the MD values. White matter disease was quantified using the Lesion Segmentation Toolbox, 20 which allows automatic detection of T2 hyperintensities based on the T2 fluidattenuated inversion recovery and T1-weighted images. This analysis derived a total white matter hyperintensity (WMH) volume for each subject.
Statistical analyses. Clinical and cognitive measures were compared across controls and PD groups in MATLAB (analysis of variance or Kruskal-Wallis, pending distributions). After analysis of FA and MD averaged across the entire skeleton, voxel-wise statistics on the skeletonized images used a permutation-based inference tool for nonparametric statistical thresholding (FSL's "randomize"). Group differences were assessed (control/PD-N/ PD-MCI/PD-D) with age, sex, years of education, and scanner software version (2 updates occurred over the acquisition period) as covariates. Separate FA and MD models excluding controls assessed the 3 PD groups (PD-N/PD-MCI/PD-D) with the same covariates plus UPDRS, disease duration, and LED. Multiple regression models investigated the association between FA/MD and aggregate cognitive z score, as well as the 4 individual cognitive domain scores, across all PD patients including all covariates. For each contrast, the null distribution was generated over 5,000 permutations and the a level set at p , 0.05, corrected for multiple comparisons using threshold-free cluster enhancement. 21 All analyses were rerun with the inclusion of WMH volume as an additional covariate, as WMH may contribute to cognitive dysfunction in PD and affect DTI metrics. 22 RESULTS Table 1 summarizes demographic and clinical details. When averaged across the entire skeleton, both median FA (x 2 5 23.7, p , 0.0001) and MD (x 2 5 27.8, p , 0.0001) showed differences across groups, with decreased FA and increased MD in PD-MCI and PD-D relative to controls and PD-N, but the cognitively impaired groups did not show a difference (Kruskal-Wallis with post hoc Bonferroni comparisons). After covarying for age, there remained a significant effect of WMH volume, with PD-MCI and PD-D exhibiting larger WMH load (log-transformed data; F 4,136 5 23.6, p , 0.0001).
Regional differences in the TBSS skeleton. Relative to controls, no significant FA decreases were identified in PD-N (figure e-1A on the Neurology ® Web site at www.neurology.org), whereas both PD-MCI ( increased MD in white matter tracts (figure e-2, B and C). With the inclusion of WMH volume as a covariate, results remained stable, but the PD-N group exhibited fewer regions of increased MD compared with controls (FA: figure 1 , A-C; MD: figure 2, A-C). Specific white matter regions exhibiting significant group differences are listed in table e-1. When the analysis was limited to PD groups only, without WMH as a covariate, PD-MCI (figure e-3A) and PD-D (figure e-3B) groups exhibited reduced FA relative to PD-N in similar but more spatially restricted regions than when compared with controls. Similarly, we identified significantly increased MD in widespread white matter tracts in both PD-MCI (figure e-3C) and PD-D (figure e-3D) relative to PD-N. Unlike their clear differences in terms of cognition, there were no significant FA or MD differences between PD-MCI and PD-D. When WMH volume was included as a covariate, a more spatially restricted pattern of decreased FA was observed in PD-MCI ( figure 3A ) and PD-D (figure 3B) relative to PD-N at a slightly more lenient threshold-free cluster enhancement-corrected p , 0.06, along with increased MD in PD-MCI (figure 3C, corrected p , 0.06) and PD-D ( figure  3D, corrected figure 4D ) in anterior white matter tracts. The attention, working memory, and processing speed score was significantly associated with MD (figure 4C) in anterior and posterior white matter and with FA in right anterior and posterior regions (data not shown). No significant association was identified between FA and any other cognitive score, nor were DTI metrics significantly associated with visuospatial/ visuoperceptual scores, UPDRS scores, disease duration, or LED.
DISCUSSION Abnormal DTI metrics along multiple white matter tracts were evident in patients with PD-MCI compared with healthy controls, but only in limited white matter tracts relative to PD-N. Localized MD changes in corpus callosum were also found in PD-N relative to controls. DTI metrics in white matter tracts correlated with aggregate cognitive measures across multiple domains. Thus, whereas small but detectable microstructural white matter differences occur in patients with PD, irrespective of cognitive status, they become substantial once formal MCI is established and may worsen only slightly with progression to dementia. This evidence is consistent with the view that PD-MCI reflects significant pathology. 4 The identification of neuroimaging markers sensitive to PD-related cognitive impairments has become a prominent goal for the field. 4, 23 Structural MRI studies have demonstrated cortical gray matter atrophy in PD-MCI relative to controls 7, 24 and even relative to PD-N in one instance, 8 but have generally failed to differentiate PD-MCI from both PD-N and PD-D. 7, 25, 26 Our DTI results (covarying for WMH volume) showed widespread microstructural differences between PD-MCI and controls, with smaller differences relative to PD-N, and support the validity of MCI in PD as a distinct condition in which significant brain pathology exists.
Few studies have explored MCI in PD with DTI. Those that did lacked formal criteria to diagnose PD-MCI and did not address the potential confounding influence of WMHs. Informal or different criteria may produce instances of misclassification. 3 One study 12 defined PD-MCI using a Clinical Dementia Rating value of 0.5 and reported widespread FA reduction relative to controls, but did not detect differences between this MCI group and PD-N or PD-D. Others demonstrated significantly reduced FA in left parietal white matter in patients with PD who did not have dementia but had impairments in executive tasks relative to those without these disturbances. 27 In the current study, more spatially extensive reduced FA and increased MD was identified in a carefully classified group of patients with PD-MCI relative to controls. Although the pattern of microstructural damage was similar to that in PD-D, our patients with PD-MCI met the recent MDS criteria and had no dementia as their activities of daily living were unimpaired. 4, 17 Although subtle, our findings suggest that patients with MCI exhibit microstructural integrity more akin to that in PD-D than PD-N. Although we did not find reduced FA in PD-N relative to controls in this study, increased MD was identified in corpus callosum, superior corona radiata, and cingulum bundle, but not the consistently identified regions of substantia nigra 28, 29 and olfactory regions. 30 In many previous studies, possible inclusion of patients with PD and subtle cognitive impairments in a single "nondementia" PD group may have substantially affected results and their interpretation by including different proportions of patients with neuropsychological deficits consistent with PD-MCI diagnosis. 10, 28, 29 Cognitive heterogeneity provides a possible explanation for the presence of FA abnormalities in nondementia groups in earlier studies and its absence in PD-N in the current study ( figure 1A ). The only other study to investigate patients with PD separately classed as normal or MCI found no FA/MD difference in those with normal cognition. 12 A consistent application of MDS MCI criteria may bring greater rigor and consistency to future studies.
It is clear that extensive microstructural damage accompanies the development of dementia in PD. A previous region of interest-based analysis demonstrated significant FA reduction in frontal, temporal, and occipital white matter in PD-D compared with controls, and in bilateral posterior cingulum bundles relative to PD without dementia. 31 A traditional voxel-based approach identified decreased FA in PD-D relative to controls in bilateral orbitofrontal, anterior and middle cingulum, right dorsolateral prefrontal, left anterior temporal, and parietal white matter. 13 Most recently, TBSS analysis was used to identify reduced FA in many major white matter tracts in PD-D relative to PD-N and healthy individuals, but did not address WMHs. 12 We also identified extensive FA reduction in PD-D relative to controls and PD-N when WMH volume was not considered. With the inclusion of WMH load, the difference between PD-D and PD-N became much more spatially localized. This is not surprising because WMHs are expected to contribute to cognitive dysfunction in PD. 22 Associations between DTI metrics and individual cognitive domains suggest that loss of microstructural integrity may contribute to cognitive impairments in PD. We identified significant association between the executive function domain score and MD in prefrontal white matter, genu, and internal and external capsules, which connect prefrontal cortex and striatum. The current DTI findings therefore provide direct microstructural evidence for the involvement of frontostriatal white matter pathology in the frontal executive network in PD. 32, 33 We also observed association between MD and attention, working memory, and processing speed in white matter tracts underlying key regions of the dorsal attention network, 33 namely, the frontal eye fields and middle temporal regions, but also extending to include anterior regions. Learning and memory domain scores correlated with MD in the anterior cingulum and lateral frontal white matter, both underlying cortical areas implicated in functional networks associated with memory. 34 Although visuospatial/visuoperceptual function was impaired in our PD-MCI and PD-D groups, we did not detect any significant relationship with DTI metrics, suggesting that non-white matter processes may have a larger influence on visuospatial function.
There are several potential limitations to the current study. First, cardiac gating was not performed during image acquisition. Although gating may improve data quality, it is time consuming and may have a negligible effect in group-level analyses. 35 Second, participants completed scanning and neuropsychological assessment with no disruption to their antiparkinsonian drug regimen. It is unlikely, however, that levodopa influenced our results because previous investigators 36 observed no significant effect of levodopa on DTI metrics. Nevertheless, we included LED as a covariate in all relevant comparisons. Third, we interpreted the absence of significant difference between PD-MCI and PD-D groups as a general similarity between the 2 groups, but it is possible that we were unable to detect subtle differences because of the smaller number in the PD-D group. Fourth, as with all DTI investigations, the direct interpretation of FA and MD in vivo is complex. While DTI metrics have been attributed to numerous processes (e.g., neuronal loss, gliosis, degradation of axonal membranes or myelin sheaths, reduced axonal fiber density, cellular density, and integrity of microtubules and neurofilaments), 9, 37 white matter alterations in PD have been associated with axonal degeneration and injury of neuronal cell bodies as a result of cytoskeletal changes. 38 Recent histologic work suggests that major contributors to the development of PD-MCI include limbic and neocortical Lewy body and Alzheimer disease histopathology, as well as cerebrovascular pathology. 39, 40 It seems likely that abnormal DTI measures along white matter tracts connecting key regions affected by PD pathology may indicate microstructural degeneration associated with cell loss, a-synuclein, and amyloid pathology. Comorbid small-vessel ischemia/WMHs may also affect DTI results. 22 Indeed, after accounting for age, we identified significantly larger WMH volume in cognitively impaired PD participants than in healthy individuals. Separate DTI analyses with and without WMH load as a covariate did not substantially change the identification of differences between PD cognitive groups and controls or any associations with cognitive scores, but did markedly reduce the spatial distribution of significant differences between cognitively impaired PD (PD-MCI, PD-D) and PD-N. Without WMH, we observed significant and widespread FA and MD difference between PD-N and both PD-MCI and PD-D, suggesting similar amounts of white matter pathology in cognitively impaired PD. When WMH volume was included, DTI differences between PD-N and cognitively impaired PD were spatially restricted to focal areas of internal and external capsule, anterior and superior corona radiata, and left inferior frontooccipital and superior longitudinal fasciculi. This suggests that substantial white matter pathology does occur in PD-MCI relative to PD-N, where some of the difference is explained by the presence of WMHs, but DTI reveals an additional and independent relationship between microstructural integrity and PD-related cognitive impairment. Future work may benefit from investigating the influence of the spatial distribution of WMHs on DTI metrics and cognition in PD.
Our findings show that even early PD is associated with some alterations in white matter pathways that worsen once significant cognitive impairments develop. Localized differences imply that functional impairment in executive function, attention, and learning and memory are influenced by these microstructural changes. Relevance as a surrogate marker requires further investigation, but our findings suggest that DTI and TBSS provide a promising method to evaluate and potentially track anatomical substrates of cognitive decline in PD.
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